Person: AKASLAN, TAHSİN ÇAĞDAŞ
Now showing 1 - 1 of 1
- PublicationOpen AccessClinical and histopathological improvement of scleromyxedema-induced microstomia after hyaluronidase injection(2022-05-01T00:00:00Z) AKASLAN, TAHSİN ÇAĞDAŞ; YILDIZ, PELİN; ONSUN, Nahide; AKASLAN, TAHSİN ÇAĞDAŞ; YILDIZ, PELİN; ONSUN, NAHIDEIntroduction Scleromyxedema is a rare primary cutaneous mucinosis characterized by numerous firm, waxy, confluent papules. Recently, intravenous immunoglobulin (IVIG) is accepted by many authors as the first-line treatment option for severe cases. We report a 69-year-old male patient who has been suffering from scleromyxedema, with reduced mouth opening. He has been on a high-dose IVIG regime for 5 years. Methods The patient stated that he had difficulty in wearing and removing his dentures because of reduced mouth opening lately. Before considering to add any other immunosuppressants to his regime, we injected 1500 IU of hyaluronidase in total in one session periorally. The patient has been told open his mouth maximum and photographs have been taken before injections and after one month. We used a photo measurement application when evaluating microstomia to increase accuracy. We also took punch biopsies in order to evaluate effect of hyaluronidase histopathologically before and one month after injections. Results One month later, he was able to reattach and remove his dentures without adding any adjuvant immunosuppressants other than hyaluronidase. Mouth opening was increased in measurements and histopathologically, mucin deposition, fibroblastic proliferation, and perivascular lymphocytic infiltration were decreased. Conclusions We think hyaluronidase is a safe, easily accessible, and effective treatment option for microstomia caused by scleromyxedema.